Be a light of hope this holiday season. Ignite more progress, restore more freedom, and inspire more hope for families living with neuromuscular disease.

Innovations in Care

We provide access to support and programs that empower the lives of people living with neuromuscular diseases.

PREVAIL Phase 3 study in generalized Myasthenia Gravis

October 17th, 2023
12 PM ET
30 minutes
On-Demand Webinar

A study by Alexion to investigate its new complement inhibitor Gefurulimab (ALXN1720) for the treatment of Myasthenia Gravis.

Speakers:

Sanjay Rakhade MD, PhD
Executive Medical Director
Alexion Astra Zeneca Rare Disease Unit

Joachim Scholz, MD
Medical Director Clinical Development and Translational Sciences
Alexion Astra Zeneca Rare Disease

Watch On-Demand

After registering, you will receive a confirmation email containing information about joining the webinar conducted on Zoom. If you have questions or comments, please contact mdapartners@mda.org

If you have questions or comments, contact mdapartners@mdausa.org

This Industry Update Webinar is sponsored by Alexion. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.

Thank you to our supporter:

Alexion

Find MDA
in your Community